𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Parkinson's disease, proteins, and prions: Milestones

✍ Scribed by C. Warren Olanow; K. McNaught


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
494 KB
Volume
26
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Parkinson's disease (PD) is characterized by protein accumulation in the form of Lewy bodies and neurites. It is thus reasonable to consider that alterations in protein handling in the form of increased production, impaired clearance, or both might be central to the etiopathogenesis of the disease. Increasing genetic, laboratory and pathologic evidence has accumulated over the past 25 years supporting this hypothesis. A vicious cycle could develop in which increased protein accumulation from any cause could lead to interference with lysosomal and proteasomal clearance mechanisms causing further protein accumulation. Eventually, protein accumulation could overwhelm the cell's defenses and lead to the formation of toxic oligomers and amyloid‐based inclusions such as Lewy bodies, disruption of critical cell processes, and ultimately neurodegeneration. More recent findings of Lewy pathology in implanted embryonic dopamine neurons in PD patients raises the intriguing possibility that PD might be a prion disorder. These concepts suggests new targets and novel candidate therapies that might be neuroprotective for PD. © 2011 Movement Disorder Society


📜 SIMILAR VOLUMES


Milestones in Parkinson's disease therap
✍ Olivier Rascol; Andres Lozano; Matthew Stern; Werner Poewe 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB

## Abstract In the mid‐1980s, the treatment of Parkinson's disease was quite exclusively centered on dopatherapy and was focusing on dopamine systems and motor symptoms. A few dopamine agonists and a monoamine oxidase B inhibitor (selegiline) were used as adjuncts in advanced Parkinson's disease. I

Milestones in Parkinson's disease—Clinic
✍ Glenda Halliday; Andrew Lees; Matthew Stern 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 350 KB 👁 1 views

## Abstract The identification of the widespread deposition of fibrillized α‐synuclein in Lewy bodies and Lewy neurites in the brains of patients with Parkinson's disease in 1997 has had a profound impact on how the disease is now conceptualized. The previous focus on the loss of the dopaminergic n

Milestones in research on the pathophysi
✍ Thomas Wichmann; Mahlon R. DeLong; Jorge Guridi; Jose A. Obeso 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 400 KB 👁 1 views

## Abstract Progress in our understanding of the mechanisms underlying the cardinal motor abnormalities of Parkinson's disease (PD), in particular akinesia and bradykinesia and their treatment, has been remarkable. Notable accomplishments include insights into the functional organization of the bas

Neuroinflammation in Alzheimer's disease
✍ P. Eikelenboom; C. Bate; W.A. Van Gool; J.J.M. Hoozemans; J.M. Rozemuller; R. Ve 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 447 KB

## Abstract Alzheimer's disease (AD) and prion disease are characterized neuropathologically by extracellular deposits of Aβ and PrP amyloid fibrils, respectively. In both disorders, these cerebral amyloid deposits are co‐localized with a broad variety of inflammation‐related proteins (complement f

Visual symptoms in Parkinson's disease a
✍ Neil K. Archibald; Mike P. Clarke; Urs P. Mosimann; David J. Burn 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

## Abstract Visual symptoms are common in PD and PD dementia and include difficulty reading, double vision, illusions, feelings of presence and passage, and complex visual hallucinations. Despite the established prognostic implications of complex visual hallucinations, the interaction between cogni